This site uses cookies to collect activity data and personalize content. By continuing to navigate this site, you agree to allow us to collect information using cookies. Learn more about how we care for your data in our privacy notice.

Accept

PATH Resources

Our online catalog indexes publications, presentations, and related resources for peers in our field.

136 Resources
136 Resources
136 Resources
    Date
  1. This fact sheet provides an overview of the novel oral polio vaccine (nOPV) program, a consortium of PATH and partners that are working to advance novel vaccine candidates that will enable complete eradication and minimize the risk of polio making a comeback.
    Published: October 2020
    Type: Resource Page
  2. This is a simple, Excel-based tool for assessing and comparing costs of pneumococcal conjugate vaccine (PCV) programs annually and for a period of 10 years with each PCV product available in the global market. It aims to help country-level policymakers compare products and estimate vaccination program costs for different PCVs. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance. Estimates of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery) are provided separately, based on limited user inputs, for two perspectives: (1) the country perspective and (2) the combined country and Gavi perspective (only relevant for Gavi-eligible countries).It is important to note that cost is only one consideration when selecting a PCV product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results, which are provided in both tables and charts. The tool is available to download in multiple languages below. For questions or support, contact PATH’s Health Economics & Outcomes Research team: HEOR@path.org.
    Published: September 2020
    Type: Resource Page
  3. This is a simple, Excel-based tool for assessing and comparing costs of rotavirus vaccination programs annually and for a period of 10 years with each rotavirus vaccine product available in the global market. It aims to help country-level policymakers compare products and estimate vaccination program costs for different rotavirus vaccines, exploring up to six different vaccine options at a time. The tool can be used by decision-makers, implementers, technical partners, and others in any country, whether or not the country is eligible for co-funding from Gavi, the Vaccine Alliance. Estimates of vaccine cost (i.e., vaccine and supplies procurement and international shipping) and vaccination program costs (i.e., vaccine cost and cost of delivery) are provided separately, based on limited user inputs, for two perspectives: (1) the country perspective and (2) the combined country and Gavi perspective (only relevant for Gavi-eligible countries).It is important to note that cost is only one consideration when selecting a rotavirus vaccine product, and users involved in decision-making around new vaccine introduction or product selection should always consider other dimensions as well. This model is meant to provide insights into the potential costs of alternative product choices and should not replace detailed budget planning once a product has been selected.A user guide is included in the file on a tab labeled “READ ME FIRST” which provides detailed instructions on how to use the tool and interpret the results, which are provided in both tables and charts. The tool is available to download in multiple languages below. For questions or support, contact PATH's Health Economics & Outcomes Research team: HEOR@path.org.
    Published: August 2020
    Type: Resource Page
  4. This brief summarizes the experience and capabilities of the PATH HPV Vaccine Team. For decades, PATH has been at the forefront of evidence-based strategies from HPV vaccine research and delivery to cervical cancer screening and treatment to ensure we best meet the needs and realities of these countries for the greatest health impact.
    Published: June 2020
    Type: Resource Page
  5. This fact sheet outlines PATH's role in providing technical assistance to countries for the planning, implementation, and evaluation of human papillomavirus (HPV) vaccination programs. The PATH HPV vaccine team’s activities are channeled through four primary work streams: Gavi, the Vaccine Alliance application support; program planning and implementation; evaluation; and cervical cancer prevention and control strategies.
    Published: June 2020
    Type: Resource Page
Load more